

Amendment to the Claims

1-7 (Canceled)

8 (Original) A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture.

9 (Previously presented) The composition of claim 8 wherein said lysosomal storage disorder is Galactosialidosis.

10 (Previously presented) The composition of claim 8 wherein said protein is protective protein/cathepsin A (PPCA).

11 (Original) The composition of claim 8 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricophasia ni*.

12 (Original) The composition of claim 11 wherein said cells are *Spodoptera frugiperda* Sf9 cells.

13 (Original) The composition of claim 8 wherein said protein is produced in the cell culture using a baculovirus expression system.

14-20 (Canceled)

21. (New) The composition of claim 8 wherein said lysosomal storage disorder is selected from the group consisting of Pompe Disease, GM1 gangliosidosis, Tay-Sachs disease, GM2 gangliosialidosis: AB Variant, Sandhoff Disease, Gaucher Disease, Krabbe Disease, Niemann-Pick Types A-D, Farber Disease, Wolman Disease, Cholesterol Ester Storage Disease, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie, Hunter Syndrome, Sanfilippo A-D, Morquio A-B, Maroteaux-Lamy, Sly Syndrome, Metachromatic Leukodystrophy, Multiple Sulfatase Deficiency, Sialidosis, I-Cell Disease, Pseudo-Hurler Polydystrophy, Mucopolipidosis IV,  $\alpha$ -Mannosidosis,  $\beta$ -Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Galactosialidosis, Schindler Disease, Cystinosis, Salla Disease, Infantile Sialic Acid Storage Disorder, Batten Disease, Infantile Neuronal Ceroid Lipofuscinosis, and Prosaposin.
22. (New) The composition of claim 8 wherein said protein is selected from the group consisting of acid  $\alpha$ -1,4 glucosidase, acid  $\alpha$ -1,6 glucosidase,  $\beta$ -galactosidase,  $\beta$ -hexosaminidase A, GM<sub>2</sub> Activator Protein,  $\beta$ -hexosaminidase A,  $\beta$ -hexosaminidase B, glucocerebrosidase,  $\beta$ -glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase,  $\alpha$ -L-iduronidase, iduronate sulfatase,  $\alpha$ -N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsulfatase B,  $\beta$ -glucuronidase, arylsulfatase A, arylsulfatase C,  $\alpha$ -Neuraminidase, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase,  $\alpha$ -mannosidase,  $\beta$ -mannosidase,  $\alpha$ -L-fucosidase, N-aspartyl- $\beta$ -glucosaminidase, protective protein/cathepsin A (PPCA),  $\alpha$ -N-acetyl-galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoyl-protein thioesterase, and Saposins A-D.

- 23 (New) The composition of claim 21 wherein said lysosomal storage disorder is Sialidosis.
- 24 (New) The composition of claim 22 wherein said protein is  $\alpha$ -Neuraminidase.